Related Experiment Video
Updated: Feb 3, 2026
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
A phase 4, open-label, single arm, multi-center study to evaluate the safety of a smallpox vaccine in previously
David Cassie1, Vanja Komlenovic1, Geraldine Parrera1
1Emergent BioSolutions Canada, 155 Innovation Drive, Winnipeg, Manitoba R3T 5Y3, Canada.
Abstract:
ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] is an attenuated vaccinia vaccine indicated in the US for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. The current study assessed the ability of a screening algorithm to identify a population of previously vaccinated individuals for whom revaccination with ACAM2000 vaccine could be used to assess safety (NCT02443623). Vaccination in this study stimulated anti-vaccinia antibodies in plasma donors for the preparation of vaccinia immune globulin intravenous (VIGIV). This was an open label, single-arm, multi-center study. The protocol criteria were designed to screen out individuals with risk factors associated with increased risk of adverse events, specifically myocarditis/pericarditis, including an algorithm to be followed in the event of symptom development. Post-vaccination safety data was collected including solicitation for symptoms of myocarditis/pericarditis. There were 4088 participants screened, of which 3032 were vaccinated, 850 failed the screening criteria and 206 were enrolled but not vaccinated. The median age was 51, ranged from 18 to 65, and was comprised of 75% males. Out of the 3032 vaccinated participants, 1420 (47%) reported 2478 adverse events (AEs), of which 1468 AEs in 1190 (39.2%) participants were considered related. Twenty-one participants (0.7%) reported severe events, serious adverse events were uncommon (0.8%), two were considered related to vaccination and there was one unrelated death. Inadvertent autoinoculation was reported in six participants but did not require medical intervention. The most frequently reported vaccination related AEs were cutaneous reactions and constitutional symptoms. Out of 3032 vaccinated participants, 65 had potential symptoms of myocarditis/pericarditis (myopericarditis) which were resolved, and there were no diagnoses of myopericarditis. Administration of ACAM2000 vaccine was well tolerated in this population of previously vaccinated participants.
Insights
ACAM2000® vaccine, used for smallpox and mpox prevention, was well-tolerated in previously vaccinated individuals. The study identified a safe population for revaccination, with most adverse events being mild cutaneous reactions or constitutional symptoms.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) is an attenuated vaccinia vaccine for individuals at high risk of smallpox or mpox.
- Previous vaccination history can influence vaccine response and safety profiles.
Purpose of the Study:
- To assess the safety of ACAM2000® vaccine in a previously vaccinated population.
- To evaluate a screening algorithm for identifying suitable candidates for ACAM2000® revaccination.
- To gather safety data, including adverse events and symptoms of myocarditis/pericarditis, following ACAM2000® administration.
Main Methods:
- An open-label, single-arm, multi-center study involving screening and vaccination phases.
- A screening algorithm was employed to exclude individuals with risk factors for adverse events, particularly myocarditis/pericarditis.
- Post-vaccination safety data, including solicited adverse events and symptoms of myopericarditis, were collected.
Main Results:
- 3032 previously vaccinated participants received ACAM2000®; 47% reported adverse events (AEs), with 39.2% considered related to vaccination.
- Most AEs were mild cutaneous reactions and constitutional symptoms; severe events were rare (0.7%).
- No cases of myocarditis/pericarditis were diagnosed, although 65 participants reported potential symptoms that resolved.
Conclusions:
- ACAM2000® vaccine was well-tolerated in this population of previously vaccinated individuals.
- The screening algorithm effectively identified a population at lower risk for severe adverse events.
- The study supports the use of ACAM2000® in previously vaccinated individuals under appropriate screening protocols.
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:28Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
01:25Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...
01:17Power Distribution in Three-phase and Single Phase Circuits
Single-Phase Power Distribution:
Single-phase circuits are typical in household settings;...
01:28Survey Safety